50% off all subscriptions! ... left. Order NowOrder Now

Weaker Stock
Today EPZM ranks #12807 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$3.37 (-6.91%)

Volume: 1M

Closed: Nov 26, 2021

Hollow Logo Score: -5.293

Epizyme Stock Forecast

$3.37 (-6.91%)

Volume: 1M

Closed: Nov 26, 2021

Score Hollow Logo -5.293

Epizyme Stock Forecast NASDAQ:EPZM

Price Target and Analyst Ratings

Most Recent Rating

On Aug 10, 2021 "HC Wainwright" gave "$36.00 - $15.00" rating for EPZM. The price target was changed from $5.86 to 9.4%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-10 $36.00 - $15.00 Target Lowered by HC Wainwright $5.50 $5.86→9.4%
2021-08-09 Downgraded by Morgan Stanley $5.86 $5.86→9.4%
2021-05-13 Equal Weight Target Lowered by Morgan Stanley $8.67 $11.00 → $10.00
2021-05-13 Market Perform - Outperform Upgraded by SVB Leerink $8.67 $12.00 → $16.00
2021-05-07 Market Perform - Outperform Upgraded by SVB Leerink $8.29
2021-05-07 Market Perform - Outperform Upgraded by SVB Leerink $8.29 $12.00 → $16.00
2021-05-07 Equal Weight Target Lowered by Morgan Stanley $8.29 $11.00 → $10.00
2021-04-26 Equal Weight Target Lowered by Morgan Stanley $8.18 $14.00 → $11.00
2021-04-19 Equal Weight Target Lowered by Morgan Stanley $7.73 $14.00 → $11.00
2021-03-30 Outperform Initiated by Credit Suisse Group $8.17 $13.00
2021-03-30 Outperform Initiated by Credit Suisse Group $8.17
2021-03-03 Overweight - Equal Weight Reiterated by Morgan Stanley $9.26 $14.00
2021-02-25 Overweight - Equal Weight Downgraded by Morgan Stanley $9.66 $14.00
2021-02-24 Target Lowered by Citigroup $10.19 $35.00 → $27.00
2021-02-05 Market Perform Reiterated by SVB Leerink $11.00
2020-12-21 Buy - Hold Downgraded by Jefferies Financial Group $12.06 $18.00 → $14.00
2020-12-21 Buy - Hold Downgraded by Jefferies Financial Group $12.06 $14.00
2020-11-09 Overweight Target Lowered by Barclays $11.45 $33.00 → $18.00
2020-11-09 Overweight Target Lowered by Morgan Stanley $11.45 $29.00 → $27.00
2020-08-05 Overweight Target Lowered by Morgan Stanley $13.03 $31.00 → $29.00
2020-06-19 Market Perform Target Lowered by SVB Leerink $18.84 $18.00 → $16.00
2020-06-19 Overweight Target Raised by Morgan Stanley $18.84 $28.00 → $31.00
2020-05-05 Hold Reiterated by Oppenheimer $18.27 $16.00 → $17.00

EPZM Stock Trend

The stock has broken the very wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($3.69) are considered to be a "second chance" to get out. According to the fan-theory $2.74 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Data

Date Bottom Mid Top
2021-11-30 $3.66 $4.13 $4.60
2021-12-01 $3.63 $4.10 $4.57
2021-12-02 $3.61 $4.08 $4.55
2021-12-03 $3.58 $4.05 $4.52
2021-12-06 $3.55 $4.02 $4.49
2021-12-07 $3.52 $4.00 $4.47
2021-12-08 $3.50 $3.97 $4.44
2021-12-09 $3.47 $3.94 $4.41
2021-12-10 $3.44 $3.91 $4.39
2021-12-13 $3.42 $3.89 $4.36
2021-12-14 $3.39 $3.86 $4.33
2021-12-15 $3.36 $3.83 $4.30
2021-12-16 $3.33 $3.81 $4.28
2021-12-17 $3.31 $3.78 $4.25
2021-12-20 $3.28 $3.75 $4.22
2021-12-21 $3.25 $3.72 $4.20
2021-12-22 $3.23 $3.70 $4.17
2021-12-23 $3.20 $3.67 $4.14
2021-12-27 $3.17 $3.64 $4.11
2021-12-28 $3.15 $3.62 $4.09
2021-12-29 $3.12 $3.59 $4.06
2021-12-30 $3.09 $3.56 $4.03
2021-12-31 $3.06 $3.54 $4.01
2022-01-03 $3.04 $3.51 $3.98
2022-01-04 $3.01 $3.48 $3.95
2022-01-05 $2.98 $3.45 $3.93
2022-01-06 $2.96 $3.43 $3.90
2022-01-07 $2.93 $3.40 $3.87
2022-01-10 $2.90 $3.37 $3.84
2022-01-11 $2.87 $3.35 $3.82

About Epizyme

Epizyme Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company’s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs). Its lead product candidate includes tazemetostat, an inhibitor of the EZH2 HMT, which is in Phase II clinical study in adults with relapsed or refractory non-Hodgkin lymphoma; and in phase II s... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT